Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to thirteen new employees on December 4, 2024. The awards include non-qualified stock options to purchase 38,568 shares at $17.17 per share and 22,264 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting at the second anniversary and the remaining in two annual installments.
The awards were approved by the Compensation Committee under Acadia's 2024 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The company focuses on neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome.
Acadia Pharmaceuticals (NASDAQ: ACAD) ha concesso premi di assunzione a tredici nuovi dipendenti il 4 dicembre 2024. I premi includono opzioni su azioni non qualificate per l'acquisto di 38.568 azioni a $17,17 per azione e 22.264 unità di azioni vincolate (RSU). Le opzioni su azioni si matureranno in quattro anni, con il 25% che si matura dopo un anno e il restante mensilmente su un periodo di 36 mesi. Le RSU si matureranno in quattro anni, con il 50% che si matura al secondo anniversario e il restante in due rate annuali.
I premi sono stati approvati dal Comitato Compensi nell'ambito del Piano di Induzione 2024 di Acadia, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). L'azienda si concentra su innovazioni nelle neuroscienze e ha sviluppato trattamenti approvati dalla FDA per la psicosi del Parkinson e la sindrome di Rett.
Acadia Pharmaceuticals (NASDAQ: ACAD) ha concedido premios de inducción a trece nuevos empleados el 4 de diciembre de 2024. Los premios incluyen opciones sobre acciones no calificadas para comprar 38,568 acciones a $17.17 por acción y 22,264 unidades de acciones restringidas (RSUs). Las opciones sobre acciones se adquirirán durante cuatro años, con el 25% adquiriéndose después de un año y el resto mensualmente durante 36 meses. Las RSUs se adquirirán durante cuatro años, con el 50% adquiriéndose en el segundo aniversario y el resto en dos pagos anuales.
Los premios fueron aprobados por el Comité de Compensación bajo el Plan de Inducción 2024 de Acadia, cumpliendo con la Regla de Cotización Nasdaq 5635(c)(4). La empresa se enfoca en descubrimientos en neurociencia y ha desarrollado tratamientos aprobados por la FDA para la psicosis del Parkinson y el síndrome de Rett.
아카디아 제약 (NASDAQ: ACAD)는 2024년 12월 4일에 13명의 신입 직원에게 유도 보상을 부여했습니다. 보상 항목에는 주당 $17.17에 38,568주를 구매할 수 있는 비자격 주식 옵션과 22,264주의 제한된 주식 단위(RSU)가 포함됩니다. 주식 옵션은 4년에 걸쳐 베스팅되며, 1년 후 25%가 베스팅되고 나머지 36개월 동안 매달 베스팅됩니다. RSU는 4년에 걸쳐 베스팅되며, 2주년에는 50%가 베스팅되고 잔여분은 두 번의 연간 할부로 지급됩니다.
이 보상은 아카디아의 2024년 유도 계획에 따라 보상 위원회에서 승인되었으며, 나스닥 상장 규칙 5635(c)(4)을 준수합니다. 이 회사는 신경 과학의 혁신에 중점을 두고 있으며, 파킨슨병 정신병 및 레트 증후군에 대한 FDA 승인 치료제를 개발했습니다.
Acadia Pharmaceuticals (NASDAQ: ACAD) a accordé des primes d'incitation à treize nouveaux employés le 4 décembre 2024. Les primes comprennent des options d'achat d'actions non qualifiées pour acheter 38 568 actions à 17,17 $ par action et 22 264 unités d'actions restreintes (RSU). Les options d'achat d'actions seront acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste mensuellement sur 36 mois. Les RSU seront acquises sur quatre ans, avec 50 % acquises à la deuxième annuellement et le reste en deux versements annuels.
Les primes ont été approuvées par le Comité de rémunération dans le cadre du Plan d'incitation 2024 d'Acadia, conformément à la Règle de cotation Nasdaq 5635(c)(4). L'entreprise se concentre sur les percées en neurosciences et a développé des traitements approuvés par la FDA pour la psychose de la maladie de Parkinson et le syndrome de Rett.
Acadia Pharmaceuticals (NASDAQ: ACAD) hat am 4. Dezember 2024 Induktionspreise an dreizehn neue Mitarbeiter vergeben. Die Preise umfassen nicht qualifizierte Aktienoptionen zum Kauf von 38.568 Aktien zu je 17,17 $ sowie 22.264 eingeschränkte Aktieneinheiten (RSUs). Die Aktienoptionen werden über vier Jahre ausgeübt, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate fällig werden. Die RSUs reifen über vier Jahre, wobei 50 % zum zweiten Jahrestag und der Rest in zwei jährlichen Raten fällig werden.
Die Preise wurden vom Vergütungsausschuss im Rahmen des Induktionsplans 2024 von Acadia genehmigt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Das Unternehmen konzentriert sich auf Durchbrüche in der Neurowissenschaft und hat von der FDA genehmigte Behandlungen für Psychosen bei Parkinsonkrankheit und Rett-Syndrom entwickelt.
- Company has FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome
- Active clinical-stage development pipeline focusing on multiple neuropsychiatric conditions
- None.
Each stock option has an exercise price per share equal to
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241216033013/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
What inducement awards did ACAD grant to new employees on December 4, 2024?
What is the vesting schedule for ACAD's December 2024 stock option grants?
How do the RSUs vest in ACAD's December 2024 inducement grants?
What FDA-approved treatments has ACAD developed?
What therapeutic areas is ACAD currently focusing on in clinical development?
